BioXcel Therapeutics, Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

NASDAQ:BTAI

BioXcel Therapeutics, Inc. Common Stock

Last Close

1.17

26/07 20:00

Market Cap

43.16M

Beta: 1.10

Volume Today

258.96K

Avg: 506.97K

PE Ratio

−0.51

PFCF: −0.67

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics